NCT00904059View on ClinicalTrials.gov

Drug-Drug Interaction Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Hepatitis C
Interventions
DRUG

BMS-650032

Capsules, Oral, 600 mg, Q12h, Days 1-7

DRUG

BMS-790052

Capsules, Oral, 60 mg, Q24h, Days 1-7

DRUG

BMS-650032

Capsules, Oral, 200 mg, Q12h, Days 8-21

DRUG

BMS-790052

Capsules, Oral, 30 mg, Q24h, Days 8-21

Trial Locations (1)

78744

Ppd Development, Lp, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00904059 - Drug-Drug Interaction Study in Healthy Subjects | Biotech Hunter | Biotech Hunter